HomeCompareSGIC vs ABBV

SGIC vs ABBV: Dividend Comparison 2026

SGIC yields 2500.00% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SGIC wins by $30.22M in total portfolio value
10 years
SGIC
SGIC
● Live price
2500.00%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.32M
Annual income
$371,702.11
Full SGIC calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — SGIC vs ABBV

📍 SGIC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGICABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGIC + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGIC pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGIC
Annual income on $10K today (after 15% tax)
$212,500.00/yr
After 10yr DRIP, annual income (after tax)
$315,946.79/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, SGIC beats the other by $294,079.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGIC + ABBV for your $10,000?

SGIC: 50%ABBV: 50%
100% ABBV50/50100% SGIC
Portfolio after 10yr
$15.21M
Annual income
$198,713.92/yr
Blended yield
1.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SGIC
No analyst data
Altman Z
-0.3
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGIC buys
0
ABBV buys
0
No recent congressional trades found for SGIC or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGICABBV
Forward yield2500.00%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$30.32M$104.7K
Annual income after 10y$371,702.11$25,725.73
Total dividends collected$21.79M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SGIC vs ABBV ($10,000, DRIP)

YearSGIC PortfolioSGIC Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$135,700$125,000.00$11,559$438.51+$124.1KSGIC
2$937,839$792,640.19$13,494$640.86+$924.3KSGIC
3$3,563,316$2,559,828.33$15,951$945.97+$3.55MSGIC
4$8,357,635$4,544,886.72$19,152$1,413.89+$8.34MSGIC
5$13,923,919$4,981,249.86$23,443$2,146.38+$13.90MSGIC
6$18,776,548$3,877,953.95$29,391$3,321.96+$18.75MSGIC
7$22,534,579$2,443,673.16$37,948$5,265.87+$22.50MSGIC
8$25,482,449$1,370,449.55$50,795$8,596.74+$25.43MSGIC
9$27,990,392$724,170.78$71,034$14,549.41+$27.92MSGIC
10$30,321,421$371,702.11$104,715$25,725.73+$30.22MSGIC

SGIC vs ABBV: Complete Analysis 2026

SGICStock

Strategic Realty Trust ('SRT') is a Real Estate Investment Trust focused on owning High Quality West Coast Urban and Street Retail Properties. The Company's Strategy is to build a portfolio of high quality urban and street retail properties in high demand locations with solid growth prospects, strong cash flows and visible value appreciation characteristics.

Full SGIC Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SGIC vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGIC vs SCHDSGIC vs JEPISGIC vs OSGIC vs KOSGIC vs MAINSGIC vs JNJSGIC vs MRKSGIC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.